Study Title

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Study Details

Description:

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

Sponsor:

Point Biopharma

Government Study Link:

NCT04647526 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.

Principal Investigator:

Luke T. Nordquist, MD

John Cohchran VA St. Louis Health Care System

St. Louis, Missouri, United States

Greater Dayton Cancer Center

Kettering, Ohio, United States

University of Colorado Hospital

Aurora, Colorado, United States

Astera Cancer Care

East Brunswick, New Jersey, United States

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

University of Michigan Hospitals

Ann Arbor, Michigan, United States

Tri-State Urologic Services

Cincinnati, Ohio, United States

University of Kentucky Chandler Medical Center

Lexington, Kentucky, United States

VA Greater Los Angeles Healthcare System

Los Angeles, California, United States

Carolina Urologic Research Center

Myrtle Beach, South Carolina, United States

Tulane University Medical Center

New Orleans, Louisiana, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

University of California Los Angeles, Nuclear Medicine Clinic

Los Angeles, California, United States

Stanford Cancer Institute

Stanford, California 94305, United States

Washington University School of Medicine

St. Louis, Missouri, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Excel Diagnostics & Nuclear Oncology Center

Houston, Texas, United States

University of Iowa Medical Center

Iowa City, Iowa, United States

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, United States

Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States

Swedish Cancer Institute Research

Seattle, Washington, United States

University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, United States

University of Texas Southwestern Medical Center

Dallas, Texas 75390, United States

New Mexico Oncology Hematology Consultants Ltd., New Mexico Cancer Center

Albuquerque, New Mexico, United States

Dallas VA Medical Center, Nuclear Medicine Service

Dallas, Texas, United States

Chesapeake Urology Associates (CUA) P.A.

Towson, Maryland, United States

Saint Louis University Hospital

St. Louis, Missouri, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

University of California Irvine Chao Family Comprehensive Cancer Center

Orange, California, United States

Canada

Jewish General Hospital

Montréal, Quebec, Canada

BC Cancer - Vancouver

Vancouver, British Columbia, Canada

Nova Scotia Health Authority

Halifax, Nova Scotia, Canada

London Health Sciences Center - Victoria Hospital

London, Ontario, Canada

CHUM - University Hospital of Montreal

Montréal, Quebec, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

CHU of Quebec - Laval University

Québec, Quebec, Canada

Sunnybrook Research Institute, Odette Cancer Center

Toronto, Ontario, Canada

France

La Timone Hospital, Nuclear Medicine Department

Marseille, Bouches-du-Rhône, France

Center Jean Perrin, Department of Medical Oncology

Clermont-Ferrand, Puy-de-Dôme, France

Claude Huriez Hospital

Lille, Nord, France

Tenon Hospital, Department of Medical Oncology

Paris, France

Montpellier Cancer Institute, Department of Nuclear Medicine

Montpellier, Hérault, France

Netherlands

St. Antonius Hospital

Nieuwegein, Utrecht, Netherlands

Erasmus University Medical Center Rotterdam

3015 GD, Rotterdam, South Holland, Netherlands

Sweden

Sahlgrenska University Hospital

Göteborg, Västra Götaland, Sweden

Norrlands University Hospital, Department of Radiation Sciences, Oncology

Umeå, Västerbotten, Sweden

United Kingdom

Charing Cross Hospital, Department of Medical Oncology

Greater London, England, United Kingdom

Royal Marsden NHS Foundation Trust - Institute of Cancer Research

Sutton, Greater London, England, United Kingdom

Contact XCancer: 402-991-8468